visualization – Oral Cancer News

Chicago ENT head and neck surgeons using VELscope Vx to enhance oral cancer surgery success rate

Source: www.menafn.com Author: press release LED Medical Diagnostics Inc. subsidiary LEDDental announced today that its VELscope Vx enhanced oral assessmentdevice will now be used by Chicago Otolaryngology Associates for oralmucosal abnormality assessment and when performing surgery on oral cancer patients. According to Chicago Otolaryngology Associates' Howard Kotler, MD,FACS, "We pride ourselves on embracing state-of-the-art technologies that allow us to provide the best patient care possible. The VELscopeVx may significantly enhance our ability to see the entire cancerous or precancerous lesion that needs to be excised, allowing us to minimize risk of additional unnecessary surgery." The VELscope Vx's fluorescence visualization technology is the first approved by the FDA and Health Canada to help surgeons determine the surgical margins when excising cancerous and precancerous tissues. The technology is also approved to help dental and medical professionals discover cancerous and precancerous tissue that might not be apparent to the unaided eye. The vast majority of the nearly 12,000 VELscope devices in use around the world are used by dental practices. Typically, when a suspicious lesion is detected by a dentist, the patient is referred to an oral surgeon or a periodontist for a surgical biopsy, which is then evaluated by an oral pathologist. If the biopsy sample is determined to be cancerous or precancerous, the patient is usually referred to an ENT head and neck surgeon for consultation and likely excision. VELscope technology was developed to address the problem of detecting all abnormal tissue, including that beneath the surface, as well as making [...]

Oral Cancer Foundation News Team - A2013-01-10T09:25:49-07:00January, 2013|Oral Cancer News|

Oral cancer: How discovery devices assist screenings

Source: www.dentistryiq.com Author: Nick Efthimiadis, Vice President, Sales & Marketing, LED Dental Inc. As the intense media attention surrounding Michael Douglas’s illness clearly demonstrated, oral cancer is increasingly in the news these days. With the unfortunate growth in the number of relatively young people contracting the disease due to exposure to the sexually-transmitted human papilla virus — specifically, the HPV-16 strain — oral cancer will only become a bigger concern for both patients and dental practices over time. In fact, the Oral Cancer Foundation recently announced that HPV-16 has now replaced tobacco as the leading cause of this disease. Sadly, one North American dies every hour of every day from oral cancer, and many of those who survive the disease are forced to deal with lengthy, painful treatment and permanent disfigurement. The main problem is that oral cancer is typically discovered in late stages, when the five-year survival rate is only around 30%. The good news: when discovered early, the survival rate leaps to 80%-to-90%. The key to early discovery is the dental practice. Ideally, each and every practice should be conducting a two-step oral cancer screening on all adult patients as part of their annual or semi-annual hygiene checkup. The first step consists of a conventional “white light” exam comprising visual inspection and palpation. The second step consists of examination with an adjunctive screening device. Fortunately, the two steps should take no more than five minutes combined. For the past several years, the adjunctive device that has [...]

Oral Cancer Foundation News Team - A2011-04-10T17:42:46-07:00April, 2011|Oral Cancer News|

Henry Schein Dental selected as exclusive distributor of VELscope Vx System in North America

Source: www.prnewswire.com Author: press release LED Dental announced today that Henry Schein Dental will be the exclusive distributor of its revolutionary new VELscope Vx Enhanced Oral Assessment system in North America. Henry Schein Dental is the U.S. Dental business of Henry Schein, Inc. (Nasdaq: HSIC), the largest provider of health care products and services to office-based practitioners. In 2006 LED Dental introduced the first generation VELscope system, which was the first to employ fluorescence visualization to help dental practitioners detect oral cancer and other forms of oral disease. The VELscope system was also the first to receive FDA and Health Canada clearance to help clinicians detect cancerous and precancerous lesions that might not be apparent to the naked eye, and to help surgeons determine the appropriate surgical margin when excision of abnormal tissue is indicated. Since then, over 6,000 VELscope systems around the world have been used to conduct over 10 million oral health exams, which is more than any other oral disease detection technology. The VELscope Vx system is the latest and most advanced generation of VELscope technology. While retaining all of the capabilities of prior generations, its cordless design provides significantly greater portability and convenience. Moreover, a price of less than half the level of prior generations makes it feasible for many practices to have one in two or more operatories. In addition, a reimbursement code has been approved for this procedure, and is honored by many insurance companies. "As the world leader in oral disease detection, it [...]

Oral Cancer Foundation News Team - A2011-01-06T19:04:11-07:00January, 2011|Oral Cancer News|

Latest generation VELscope device approved for sale by Health Canada

Source: www.sfgate.com Author: staff LED Dental Inc. announced today that its VELscope Vx Enhanced Oral Assessment system was granted a medical device license and approved for sale by Health Canada. The VELscope Vx system's unique cordless design and affordable pricing make it easier than ever for dental practices to detect oral cancer and other forms of oral disease. The first-generation VELscope device was introduced in 2006, with the second-generation version launching two years later. In total, LED Dental has sold almost 6,000 units of the two devices, which have been used to conduct almost 10 million enhanced oral soft tissue exams worldwide. Oral soft tissue exams not only help detect all types of oral disease but are also a key element of an oral cancer screening protocol. Today, VELscope fluorescence visualization technology is used to conduct more enhanced oral exams than any other detection technology in the world. "We are extremely excited about the potential of the VELscope Vx system to significantly increase the number of dental practices conducting oral cancer screenings," said Peter Whitehead, founder and CEO of LED Dental. "The device's portability makes it easy to transport between operatories within the dental practice, and its attractive pricing makes it possible for practices to charge very low exam fees to their patients." Oral cancer kills one North American every hour of every day. According to the SEER database, oral cancer has a higher mortality rate than several better-publicized cancers, such as cervical cancer and testicular cancer. Some oral cancers [...]

Oral Cancer Foundation News Team - A2010-10-20T08:46:07-07:00October, 2010|Oral Cancer News|

VELscope named one of top 100 products

Source: www.oralhealthjournal.com Author: press release LED Dental Inc. announced today that its VELscope system was named one of Top 100 Products of 2009 by Dentistry Today. Ralph Green, D.D.S., M.B.A., president and CEO of LED Dental's parent, LED Medical Diagnostics, said, “When you consider that there are over 50,000 products in the dental industry, to be named one of the top 100 products for three consecutive years is quite an honor." Since its introduction, over 4,500 systems have been sold worldwide, and over 4.5 million VELscope examinations have been conducted. LED Dental estimates that over 3 million examinations will be conducted in 2009 alone. The tissue fluorescence visualization technology platform on which the VELscope system is based is the culmination of over $50 million in research funded by the National Institutes of Health and other respected institutions and conducted by such leading organizations as the British Columbia Cancer Agency and the University of Texas's M.D. Anderson Cancer Center. The VELscope system also helps clinicians discover precancerous lesions and many other types of oral mucosal abnormalities. Independent surveys of dental practices using the VELscope system indicate extremely high satisfaction among clinicians and patients alike. Clinicians report satisfaction levels of 90% and higher for the VELscope system’s ability to detect lesions that otherwise would have been missed, for ease of incorporation into the practice, and for patient comfort and convenience. Surveys also indicate that VELscope exams take only 2-to-3 minutes, and that patients appreciate the fact that no distasteful rinses or messy [...]

Oral Cancer Foundation News Team - A2009-06-05T05:57:01-07:00June, 2009|Oral Cancer News|